Quarterly ResultAug 5, 2026, 04:10 PM
Mustang Bio Q2 Net Loss $1.07M; Cash $15.15M; Nasdaq Non-Compliance
AI Summary
Mustang Bio reported a net loss of $1.07 million for the second quarter of 2026, an increase from $0.76 million in the same period last year. The company's cash and cash equivalents decreased to $15.15 million as of June 30, 2026, from $17.27 million at the end of 2025. Mustang Bio also disclosed non-compliance with Nasdaq's minimum bid price rule and anticipates continued operating losses and negative cash flows, though it believes it has sufficient cash for at least twelve months.
Key Highlights
- Q2 2026 net loss was $1.07 million, up from $0.76 million in Q2 2025.
- Cash and cash equivalents stood at $15.15 million as of June 30, 2026.
- Total assets decreased to $15.61 million from $17.59 million at December 31, 2025.
- Company is not in compliance with Nasdaq's minimum bid price rule.
- Expects continued operating losses and negative operating cash flows.
- Believes it has sufficient cash to fund operations for at least twelve months.
- Accrued $1.4 million for asset repurchase, payment delayed due to low net assets.
- Total operating expenses for Q2 2026 increased to $1.17 million.
Price Impact
More from MBIO